1 rich Libsyn https://www.libsyn.com 90 600 Inflammation has&amp;nbsp;emerged&amp;nbsp;as a critical contributor to the pathogenesis and clinical outcomes of cardiovascular disease (CVD), with growing evidence highlighting the prognostic relevance of residual inflammatory risk. Notably, residual inflammation measured by high-sensitivity C-reactive protein (hsCRP)&amp;nbsp;remains&amp;nbsp;a strong predictor of recurrent cardiovascular events, supporting the case for more universal CRP screening. Despite advances such as interleukin‑6–targeted therapies, implementation&amp;nbsp;remains&amp;nbsp;limited, as clinicians are unlikely to treat what they do not routinely measure. Addressing current gaps in inflammatory risk assessment presents both a challenge and an opportunity to better personalize CVD prevention and treatment strategies.&amp;nbsp; &amp;nbsp;In this interview,&amp;nbsp;W. Douglas Weaver MD,&amp;nbsp;MACC&amp;nbsp;and Paul&amp;nbsp;M. Ridker, MD, MPH, FACC&amp;nbsp;discuss&amp;nbsp;Inflammation in CVD: A 2025 ACC Scientific Statement. &amp;nbsp; ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research http://accelaccorg.libsyn.com/website <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/41249475/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/201827010